Schroder Investment Management Group Takes $41.38 Million Position in Cencora, Inc. (NYSE:COR)

Schroder Investment Management Group purchased a new position in shares of Cencora, Inc. (NYSE:COR - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 184,162 shares of the company's stock, valued at approximately $41,378,000. Schroder Investment Management Group owned approximately 0.10% of Cencora as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in the stock. Hickory Asset Management Inc. bought a new position in shares of Cencora in the fourth quarter worth about $572,000. Sylvest Advisors LLC bought a new position in Cencora in the 4th quarter worth approximately $1,105,000. Insight Wealth Strategies LLC lifted its holdings in shares of Cencora by 124.6% during the fourth quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company's stock worth $4,549,000 after buying an additional 11,232 shares during the last quarter. Vontobel Holding Ltd. boosted its position in shares of Cencora by 46.9% in the fourth quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company's stock valued at $1,403,000 after acquiring an additional 1,995 shares during the period. Finally, Thurston Springer Miller Herd & Titak Inc. grew its stake in shares of Cencora by 71.1% in the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,048 shares of the company's stock worth $1,583,000 after acquiring an additional 2,928 shares during the last quarter. Institutional investors own 97.52% of the company's stock.

Insiders Place Their Bets

In other Cencora news, CEO Robert P. Mauch sold 4,970 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $255.00, for a total value of $1,267,350.00. Following the transaction, the chief executive officer now owns 51,070 shares of the company's stock, valued at approximately $13,022,850. The trade was a 8.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Lazarus Krikorian sold 2,000 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $260.06, for a total value of $520,120.00. Following the sale, the chief accounting officer now owns 20,154 shares in the company, valued at $5,241,249.24. The trade was a 9.03 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 30,675 shares of company stock valued at $8,034,778. 10.80% of the stock is currently owned by insiders.

Remove Ads

Cencora Price Performance

Shares of COR stock traded down $10.07 during trading hours on Friday, hitting $279.29. The company had a trading volume of 4,404,535 shares, compared to its average volume of 1,472,314. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $296.65. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The firm's fifty day moving average is $257.28 and its 200 day moving average is $242.81. The firm has a market capitalization of $54.16 billion, a price-to-earnings ratio of 39.73, a PEG ratio of 1.31 and a beta of 0.55.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, sell-side analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were given a $0.55 dividend. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.79%. Cencora's dividend payout ratio (DPR) is presently 31.29%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on COR. Wells Fargo & Company increased their price target on shares of Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a report on Friday, March 14th. Evercore ISI increased their target price on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. StockNews.com raised Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Finally, JPMorgan Chase & Co. upped their price target on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a report on Friday, January 24th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, Cencora presently has a consensus rating of "Moderate Buy" and a consensus target price of $280.20.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.